WO2021262910A3 - Tubulysines et conjugués tubulysines-protéines - Google Patents

Tubulysines et conjugués tubulysines-protéines Download PDF

Info

Publication number
WO2021262910A3
WO2021262910A3 PCT/US2021/038781 US2021038781W WO2021262910A3 WO 2021262910 A3 WO2021262910 A3 WO 2021262910A3 US 2021038781 W US2021038781 W US 2021038781W WO 2021262910 A3 WO2021262910 A3 WO 2021262910A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
tubulysins
tubulysin conjugates
conjugates
tubulysin
Prior art date
Application number
PCT/US2021/038781
Other languages
English (en)
Other versions
WO2021262910A2 (fr
Inventor
Amy Han
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020227046382A priority Critical patent/KR20230028325A/ko
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Priority to JP2022580159A priority patent/JP2023533218A/ja
Priority to MX2022015769A priority patent/MX2022015769A/es
Priority to MA58646A priority patent/MA58646A1/fr
Priority to EP21742993.5A priority patent/EP4171653A2/fr
Priority to CN202180044933.9A priority patent/CN115867563A/zh
Priority to BR112022024361A priority patent/BR112022024361A2/pt
Priority to AU2021296449A priority patent/AU2021296449A1/en
Priority to IL299254A priority patent/IL299254A/en
Priority to CA3185601A priority patent/CA3185601A1/fr
Publication of WO2021262910A2 publication Critical patent/WO2021262910A2/fr
Publication of WO2021262910A3 publication Critical patent/WO2021262910A3/fr
Priority to CONC2022/0019161A priority patent/CO2022019161A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des composés, des compositions et des méthodes pour le traitement de maladies et de troubles associés au cancer, comprenant des tubulysines et des conjugués protéine (par ex. anticorps) médicament associés.
PCT/US2021/038781 2020-06-24 2021-06-23 Tubulysines et conjugués tubulysines-protéines WO2021262910A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN202180044933.9A CN115867563A (zh) 2020-06-24 2021-06-23 微管溶素及蛋白质-微管溶素偶联物
JP2022580159A JP2023533218A (ja) 2020-06-24 2021-06-23 ツブリシン及びタンパク質－ツブリシンコンジュゲート
MX2022015769A MX2022015769A (es) 2020-06-24 2021-06-23 Tubulisinas y conjugados de proteina-tubulisina.
MA58646A MA58646A1 (fr) 2020-06-24 2021-06-23 Tubulysines et conjugués tubulysines-protéines
EP21742993.5A EP4171653A2 (fr) 2020-06-24 2021-06-23 Tubulysines et conjugués tubulysines-protéines
KR1020227046382A KR20230028325A (ko) 2020-06-24 2021-06-23 튜불리신 및 단백질-튜불리신 접합체
BR112022024361A BR112022024361A2 (pt) 2020-06-24 2021-06-23 Tubulisinas e conjugados de proteína-tubulisina
CA3185601A CA3185601A1 (fr) 2020-06-24 2021-06-23 Tubulysines et conjugues tubulysines-proteines
IL299254A IL299254A (en) 2020-06-24 2021-06-23 Tubulysins and protein-tubulysin conjugates
AU2021296449A AU2021296449A1 (en) 2020-06-24 2021-06-23 Tubulysins and protein-tubulysin conjugates
CONC2022/0019161A CO2022019161A2 (es) 2020-06-24 2022-12-28 Tubulisinas y conjugados de proteína-tubulisina

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043771P 2020-06-24 2020-06-24
US63/043,771 2020-06-24

Publications (2)

Publication Number Publication Date
WO2021262910A2 WO2021262910A2 (fr) 2021-12-30
WO2021262910A3 true WO2021262910A3 (fr) 2022-04-21

Family

ID=76959103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/038781 WO2021262910A2 (fr) 2020-06-24 2021-06-23 Tubulysines et conjugués tubulysines-protéines

Country Status (14)

Country Link
US (1) US20230069722A1 (fr)
EP (1) EP4171653A2 (fr)
JP (1) JP2023533218A (fr)
KR (1) KR20230028325A (fr)
CN (1) CN115867563A (fr)
AU (1) AU2021296449A1 (fr)
BR (1) BR112022024361A2 (fr)
CA (1) CA3185601A1 (fr)
CL (1) CL2022003715A1 (fr)
CO (1) CO2022019161A2 (fr)
IL (1) IL299254A (fr)
MA (1) MA58646A1 (fr)
MX (1) MX2022015769A (fr)
WO (1) WO2021262910A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230158005A (ko) 2021-03-18 2023-11-17 씨젠 인크. 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출
WO2023129518A1 (fr) 2021-12-29 2023-07-06 Regeneron Pharmaceuticals, Inc. Tubulysines et conjugués protéine-tubulysine

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055562A1 (fr) * 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysines et leurs procédés de préparation
WO2011017249A1 (fr) * 2009-08-03 2011-02-10 Medarex, Inc. Composés antiprolifératifs, leurs conjugués, procédés pour ceux-ci et utilisations de ceux-ci
WO2014009774A1 (fr) * 2012-07-12 2014-01-16 Hangzhou Dac Biotech Co., Ltd Conjugués de molécule de liaison cellulaire et d'agents cytotoxiques
WO2014126836A1 (fr) * 2013-02-14 2014-08-21 Bristol-Myers Squibb Company Composés de tubulysine, procédés d'élaboration et d'utilisation correspondants
WO2015113760A1 (fr) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Composés de tubulysine cytotoxiques pour la conjugaison
WO2015157594A1 (fr) * 2014-04-11 2015-10-15 Medimmune Llc Dérivés de tubulysine
WO2016040684A1 (fr) * 2014-09-11 2016-03-17 Seattle Genetics, Inc Administration ciblée de substances médicamenteuses contenant une amine tertiaire
WO2016077260A1 (fr) * 2014-11-10 2016-05-19 Bristol-Myers Squibb Company Analogues de tubulysine et procédés de production et d'utilisation
WO2017134547A1 (fr) * 2016-02-01 2017-08-10 Pfizer Inc. Analogues de la tubulysine et leurs procédés de préparation
WO2017147542A2 (fr) * 2016-02-26 2017-08-31 Regeneron Pharmaceuticals, Inc. Conjugaison optimisée d'anticorps spécifique d'un site de transglutaminase
WO2017196598A1 (fr) * 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Conjugués anticorps-médicaments d'analogues de la tubulysine à stabilité améliorée
WO2018058001A1 (fr) * 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations
WO2019094395A2 (fr) * 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Lieurs hydrophiles pour conjugués anticorps-médicament
WO2020132658A2 (fr) * 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Tubulysines et conjugués tubulysines-protéines
WO2020258893A1 (fr) * 2019-06-24 2020-12-30 Hangzhou Dac Biotech Co., Ltd Formulation d'un conjugué d'un analogue de tubulysine à une molécule de liaison cellulaire
WO2021174113A1 (fr) * 2020-02-28 2021-09-02 Regeneron Pharmaceuticals, Inc. Molécules bispécifiques de liaison à l'antigène qui se lient à her2, et leurs procédés d'utilisation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (fr) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
EP2148886B1 (fr) 2007-05-10 2014-02-19 R & D Biopharmaceuticals Gmbh Dérivés de tubulysine
CA2687178C (fr) 2007-05-23 2014-02-04 Ventana Medical Systems, Inc. Supports polymeres pour immunohistochimie et hybridation in situ
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
EP2528625B1 (fr) 2010-04-15 2013-07-10 Spirogen Sàrl Pyrrolobenzodiazépines et conjugués de celles-ci
WO2012005982A2 (fr) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Rapporteur pour une terminaison par la arn polymérase ii
CA2837167A1 (fr) 2011-05-27 2012-12-06 Ambrx, Inc. Compositions contenant des derives de dolastatine lies a des acides amines non naturel
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP6166728B2 (ja) 2011-10-14 2017-07-19 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
EP2751111B1 (fr) 2011-10-14 2017-04-26 MedImmune Limited Dérivés asymmetriques de bis-(5H-pyrrolo[2,1-c][1,4]benzodiazépin-5-one) pour le traitement de maladies prolifératives ou auto-immunes
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
KR101961976B1 (ko) 2011-10-14 2019-03-25 시애틀 지네틱스, 인크. 피롤로벤조디아제핀 및 표적 접합체
WO2013068874A1 (fr) 2011-11-11 2013-05-16 Pfizer Inc. Conjugués anticorps-médicament
EP2911699B1 (fr) 2012-10-23 2017-11-15 SynAffix B.V. Anticorps modifié, conjugué d'anticorps et procédés de préparation
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055562A1 (fr) * 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysines et leurs procédés de préparation
WO2011017249A1 (fr) * 2009-08-03 2011-02-10 Medarex, Inc. Composés antiprolifératifs, leurs conjugués, procédés pour ceux-ci et utilisations de ceux-ci
WO2014009774A1 (fr) * 2012-07-12 2014-01-16 Hangzhou Dac Biotech Co., Ltd Conjugués de molécule de liaison cellulaire et d'agents cytotoxiques
WO2014126836A1 (fr) * 2013-02-14 2014-08-21 Bristol-Myers Squibb Company Composés de tubulysine, procédés d'élaboration et d'utilisation correspondants
WO2015113760A1 (fr) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Composés de tubulysine cytotoxiques pour la conjugaison
WO2015157594A1 (fr) * 2014-04-11 2015-10-15 Medimmune Llc Dérivés de tubulysine
WO2016040684A1 (fr) * 2014-09-11 2016-03-17 Seattle Genetics, Inc Administration ciblée de substances médicamenteuses contenant une amine tertiaire
WO2016077260A1 (fr) * 2014-11-10 2016-05-19 Bristol-Myers Squibb Company Analogues de tubulysine et procédés de production et d'utilisation
WO2017134547A1 (fr) * 2016-02-01 2017-08-10 Pfizer Inc. Analogues de la tubulysine et leurs procédés de préparation
WO2017147542A2 (fr) * 2016-02-26 2017-08-31 Regeneron Pharmaceuticals, Inc. Conjugaison optimisée d'anticorps spécifique d'un site de transglutaminase
WO2017196598A1 (fr) * 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Conjugués anticorps-médicaments d'analogues de la tubulysine à stabilité améliorée
WO2018058001A1 (fr) * 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations
WO2019094395A2 (fr) * 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Lieurs hydrophiles pour conjugués anticorps-médicament
WO2020132658A2 (fr) * 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Tubulysines et conjugués tubulysines-protéines
WO2020258893A1 (fr) * 2019-06-24 2020-12-30 Hangzhou Dac Biotech Co., Ltd Formulation d'un conjugué d'un analogue de tubulysine à une molécule de liaison cellulaire
WO2021174113A1 (fr) * 2020-02-28 2021-09-02 Regeneron Pharmaceuticals, Inc. Molécules bispécifiques de liaison à l'antigène qui se lient à her2, et leurs procédés d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDRE H. ST. AMANT ET AL: "A Reactive Antibody Platform for One-Step Production of Antibody-Drug Conjugates through a Diels-Alder Reaction with Maleimide", BIOCONJUGATE CHEMISTRY, vol. 30, 5 August 2019 (2019-08-05), US, pages 2340 - 2348, XP055614773, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.9b00436 *
LEANNA R. STABEN ET AL: "Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors", ACS MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 10, 5 September 2017 (2017-09-05), US, pages 1037 - 1041, XP055532485, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.7b00243 *

Also Published As

Publication number Publication date
MA58646A1 (fr) 2023-08-31
CO2022019161A2 (es) 2022-12-30
CN115867563A (zh) 2023-03-28
KR20230028325A (ko) 2023-02-28
BR112022024361A2 (pt) 2022-12-27
MX2022015769A (es) 2023-01-19
JP2023533218A (ja) 2023-08-02
AU2021296449A1 (en) 2023-01-19
WO2021262910A2 (fr) 2021-12-30
CL2022003715A1 (es) 2023-07-07
IL299254A (en) 2023-02-01
CA3185601A1 (fr) 2021-12-30
US20230069722A1 (en) 2023-03-02
EP4171653A2 (fr) 2023-05-03

Similar Documents

Publication Publication Date Title
WO2020132658A3 (fr) Tubulysines et conjugués tubulysines-protéines
WO2021021979A3 (fr) Inhibiteurs de hdac6 et leurs utilisations
AU2003218989A1 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
WO2006113909A3 (fr) Agents de liaison anti-cd70 humanises et utilisations
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
WO2003043583A3 (fr) Traitement des troubles immunologiques au moyen des anticorps anti-cd30
ATE472338T1 (de) Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
WO2002078766A3 (fr) Polytherapie
MX2022002592A (es) Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo.
EP1820503A3 (fr) Dérivés d'aminoindazole actifs en tant qu'inhibiteurs de la kinase, leur procédé de préparation et compositions pharmaceutiques les contenant
ATE459357T1 (de) Kombinationen zur behandlung von multiplem myelom
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
WO2006096489A3 (fr) Compositions d'anticorps anti-m-csf a niveaux d'endotoxine reduits
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
WO2006095029A3 (fr) Conjugues di-polymere-proteine et procedes de preparation de ceux-ci
MX2021005822A (es) Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteinas de los mismos para usarse como agonistas de lxr.
WO2021207433A3 (fr) Épitopes d'anticorps neutralisant le sars-cov-2
WO2023235838A3 (fr) Modificateurs d'épissage ciblant l'arn pour le traitement d'affections et de maladies associées à foxp3
CL2022001970A1 (es) Conjugados de proteínas-compuestos antivirales
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2024002407A (es) Anticuerpos y conjugados sirp-alfa.
WO2020186111A3 (fr) Anticorps se liant à vista et leurs utilisations
WO2004078130A3 (fr) Proteines d'interaction posh et procedes connexes
WO2023009754A3 (fr) Conjugués protéine-composé antiviral

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21742993

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3185601

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 202217069026

Country of ref document: IN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022024361

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2022580159

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112022024361

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20221129

ENP Entry into the national phase

Ref document number: 2021296449

Country of ref document: AU

Date of ref document: 20210623

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021742993

Country of ref document: EP

Effective date: 20230124